Get started
Award

Hhsn272200800008c

Funded outputs count: 35
Funder award ID: HHSN272200800008C
OpenAlex ID: G7204274223
Utilizing an Opportunistic Clinical Study and Population‐Based Pharmacokinetic Models to Identify Rational Empiric Dosing Regimens for Piperacillin–Tazobactam in Critically Ill Patients
2024 · Joshua A. Reeder, C. Buddy Creech, et al. · The Journal of Clinical Pharmacology · 4
PDF
Establishment of human post-vaccination SARS-CoV-2 standard reference sera
2024 · Jinhua Xiang, Louis Katz, et al. · Journal of Immunological Methods · 3
Immunogenicity and safety of varying dosages of a fifth-wave influenza A/H7N9 inactivated vaccine given with and without AS03 adjuvant in healthy adults
2023 · Lisa A. Jackson, Jack T. Stapleton, et al. · Vaccine · 6
Population pharmacokinetics and target attainment analyses to identify a rational empirical dosing strategy for cefepime in critically ill patients
2023 · Guohua An, C Buddy Creech, et al. · Journal of Antimicrobial Chemotherapy · 8
PDF
Evaluation of Empirical Dosing Regimens for Meropenem in Intensive Care Unit Patients Using Population Pharmacokinetic Modeling and Target Attainment Analysis
2023 · Guohua An, C. Buddy Creech, et al. · Antimicrobial Agents and Chemotherapy · 16
PDF
Importance of Utilizing Natural Isotopologue Transitions in Expanding the Linear Dynamic Range of LC-MS/MS Assay for Small-Molecule Pharmacokinetic Sample Analysis – A Mini-review
2021 · Thanh Bach, Guohua An · Journal of Pharmaceutical Sciences · 5
Population Pharmacokinetic-Pharmacodynamic Model of Oxfendazole in Healthy Adults in a Multiple Ascending Dose and Food Effect Study and Target Attainment Analysis
2021 · Thanh Bach, Gregory A. Deye, et al. · Antimicrobial Agents and Chemotherapy · 5
Human Antibody Responses Following Vaccinia Immunization Using Protein Microarrays and Correlation With Cell-Mediated Immunity and Antibody-Dependent Cellular Cytotoxicity Responses
2021 · Sharon E Frey, Jack T Stapleton, et al. · The Journal of Infectious Diseases · 19
Population Pharmacokinetic Model of Oxfendazole and Metabolites in Healthy Adults following Single Ascending Doses
2021 · Thanh Bach, Daryl J. Murry, et al. · Antimicrobial Agents and Chemotherapy · 8
Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older
2021 · Patricia Winokur, Hana M. El Sahly, et al. · Vaccine · 10
Vaccine‐related major cutaneous reaction size correlates with cellular‐mediated immune responses after tularaemia immunisation
2021 · Rosangela Salerno‐Gonçalves, Wilbur H Chen, et al. · Clinical & Translational Immunology · 9
PDF
Pharmacokinetics, Safety, and Tolerability of Oxfendazole in Healthy Adults in an Open-Label Phase 1 Multiple Ascending Dose and Food Effect Study
2020 · Thanh Bach, Shirley Galbiati, et al. · Antimicrobial Agents and Chemotherapy · 27
High dose trivalent influenza vaccine compared to standard dose vaccine in patients with rheumatoid arthritis receiving TNF-alpha inhibitor therapy and healthy controls: Results of the DMID 10-0076 randomized clinical trial
2020 · Jack T. Stapleton, Nancy Wagner, et al. · Vaccine · 18
Aspects of matrix and analyte effects in clinical pharmacokinetic sample analyses using LC-ESI/MS/MS – Two case examples
2020 · Guohua An, Thanh Bach, et al. · Journal of Pharmaceutical and Biomedical Analysis · 14
Safety and immunogenicity of unadjuvanted subvirion monovalent inactivated influenza H3N2 variant (H3N2v) vaccine in children and adolescents
2019 · Flor M. Munoz, Evan J. Anderson, et al. · Vaccine · 6
PDF
Development and validation of a simple, fast, and sensitive LC/MS/MS method for the quantification of oxfendazole in human plasma and its application to clinical pharmacokinetic study
2019 · Thanh Bach, SoHyun Bae, et al. · Journal of Pharmaceutical and Biomedical Analysis · 16
Pharmacokinetics, Safety, and Tolerability of Oxfendazole in Healthy Volunteers: a Randomized, Placebo-Controlled First-in-Human Single-Dose Escalation Study
2019 · Guohua An, Daryl J. Murry, et al. · Antimicrobial Agents and Chemotherapy · 44
Mupirocin for Staphylococcus aureus Decolonization of Infants in Neonatal Intensive Care Units
2018 · Karen L. Kotloff, Debbie-Ann T. Shirley, et al. · PEDIATRICS · 42
Quantification of Cefepime, Meropenem, Piperacillin, and Tazobactam in Human Plasma Using a Sensitive and Robust Liquid Chromatography-Tandem Mass Spectrometry Method, Part 1: Assay Development and Validation
2018 · Ronilda D'Cunha, Thanh Bach, et al. · Antimicrobial Agents and Chemotherapy · 41
Quantification of Cefepime, Meropenem, Piperacillin, and Tazobactam in Human Plasma Using a Sensitive and Robust Liquid Chromatography-Tandem Mass Spectrometry Method, Part 2: Stability Evaluation
2018 · Ronilda D'Cunha, Thanh Bach, et al. · Antimicrobial Agents and Chemotherapy · 28
PDF
Tularemia vaccine: Safety, reactogenicity, “Take” skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain – A phase 2 randomized clinical Trial
2017 · Mark J. Mulligan, Jack T. Stapleton, et al. · Vaccine · 34
CD11a and CD49d enhance the detection of antigen-specific T cells following human vaccination
2017 · Allison F. Christiaansen, Upasna Gaur Dixit, et al. · Vaccine · 52
Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial
2017 · Lisa A. Jackson, Sharon E. Frey, et al. · Vaccine · 31
Priming Vaccination With Influenza Virus H5 Hemagglutinin Antigen Significantly Increases the Duration of T cell Responses Induced by a Heterologous H5 Booster Vaccination
2016 · Daniel F. Hoft, Kathleen Lottenbach, et al. · The Journal of Infectious Diseases · 8
Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine
2015 · Innocent N. Mbawuike, Robert L. Atmar, et al. · Vaccine · 5
Year
Topic